Its share rose by 25% over two days after its Moraiya facility passed an inspection by the US drug regulator. Cadila did transfer some of these filings to other sites, to avoid losing out on revenues from relatively significant products. This was better than not launching at all, but would have been less remunerative than a drug made at Moraiya. A results note from Prabhudas Lilladher said that lack of meaningful generic approvals due to the Moraiya issue was affecting US and EU sales. In December 2015, the company said 74 filings were done from Moraiya but new filings were being done from unaffected facilities.

Source: Mint February 20, 2017 02:18 UTC